These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1110038)

  • 21. Management of drug resistant tuberculosis.
    Supcharoen S
    Bull Int Union Tuberc; 1974 Aug; 49 suppl 1():286-7. PubMed ID: 4468025
    [No Abstract]   [Full Text] [Related]  

  • 22. [Comparative study of the concordance of results of determination of the activity of ornithine carbamoyltransferase, alanine transaminase and bilirubin in blood serum and the assessment of hepatic function in patients with pulmonary tuberculosis treated with drugs with special reference to hepatotoxic drugs].
    Pregowski W
    Gruzlica; 1973; 41(5):431-40. PubMed ID: 4710619
    [No Abstract]   [Full Text] [Related]  

  • 23. [Methods of therapy of patients with chronic destructive pulmonary tuberculosis].
    Utkin VV; Rudoĭ NM
    Klin Med (Mosk); 1968 Dec; 46(12):36-43. PubMed ID: 5737381
    [No Abstract]   [Full Text] [Related]  

  • 24. [Chemotherapy of pulmonary tuberculosis].
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1984 Aug; 7(4):194-7. PubMed ID: 6543765
    [No Abstract]   [Full Text] [Related]  

  • 25. [Enzymatic parameters of the liver function in patients with active pulmonary tuberculosis and adverse reactions to chemotherapeutic drugs].
    Bondarenko VP
    Probl Tuberk; 1979 Nov; (11):37-40. PubMed ID: 530967
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effectiveness of alpha-tocopherol in eliminating and preventing the hepatotoxic action of tuberculostatics].
    Grechin SA; Suslov EI; Mel'nik VP; Shuripa VP; Protsiuk RG
    Vrach Delo; 1987 Mar; (3):60-2. PubMed ID: 3590706
    [No Abstract]   [Full Text] [Related]  

  • 27. [Dynamics of the release of bacilli and the closing of caverns in newly identified tuberculosis patients undergoing different chemotherapeutic regimens].
    Muratov VV; Pashkov IuN; Pospelov VV
    Probl Tuberk; 1981 Dec; (12):30-4. PubMed ID: 6801646
    [No Abstract]   [Full Text] [Related]  

  • 28. [Results of treatment of coniotuberculosis with a combination of antibacterial preparations and dexamethasone].
    Savenkov DI; Galushka FP; Rodkina BS; Bortnikov AF
    Probl Tuberk; 1973; 51(3):37-9. PubMed ID: 4771051
    [No Abstract]   [Full Text] [Related]  

  • 29. [Comparative characteristics of the use of rifadin and ethambutol in the complex treatment of patients with fibro-cavernous pulmonary tuberculosis].
    Tarasova EF; Sagalovich VIa
    Probl Tuberk; 1974; (12):26-30. PubMed ID: 4445131
    [No Abstract]   [Full Text] [Related]  

  • 30. [Prednisolone and anabolic steroids in the combined treatment of pulmonary tuberculosis in the middle-aged and elderly].
    Berezitskiĭ AV; Bal'tseva LB
    Probl Tuberk; 1982 Nov; (11):44-8. PubMed ID: 7156104
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pathogenetic drugs in the treatment of destructive pulmonary tuberculosis in adolescents and adults].
    Buĭko RG; Maksimova NM
    Probl Tuberk; 1984 Jan; (1):45-9. PubMed ID: 6422459
    [No Abstract]   [Full Text] [Related]  

  • 32. [Protective effect of silibinin on liver injury induced by antituberculosis drugs].
    Li J; Lin WF; Pan YY; Zhu XY
    Zhonghua Gan Zang Bing Za Zhi; 2010 May; 18(5):385-6. PubMed ID: 20510009
    [No Abstract]   [Full Text] [Related]  

  • 33. [Differential pathogenetic therapy in the complex treatment of patients with destructive pulmonary tuberculosis].
    Molotkov VN; Ivaniuta OM; Bystritskaia VI; Mel'nik VN
    Probl Tuberk; 1982 Feb; (2):45-8. PubMed ID: 7063479
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antimycobacterial therapy in processes caused by primarily resistant bacteria].
    De Michele G
    Arch Monaldi; 1972; 27(4):487-94. PubMed ID: 4680310
    [No Abstract]   [Full Text] [Related]  

  • 35. [Certain indicators of liver function in patients with disseminated destructive pulmonary tuberculosis after intravenous administration of drugs].
    Ganushchak MM; Dubosarskiĭ AI
    Probl Tuberk; 1973; 51(3):45-7. PubMed ID: 4771054
    [No Abstract]   [Full Text] [Related]  

  • 36. [Side effects of antituberculous drugs observed within six months after admission. Tuberculosis Research Committee, Ryoken (author's transl)].
    Kekkaku; 1975 Jun; 50(6):161-7. PubMed ID: 1185917
    [No Abstract]   [Full Text] [Related]  

  • 37. [Polychemotherapy of patients with chronic destructive forms of pulmonary tuberculosis].
    Mamolat AS; Bialik IB
    Probl Tuberk; 1988; (4):13-6. PubMed ID: 3420076
    [No Abstract]   [Full Text] [Related]  

  • 38. [Chemotherapy in combination with the rapid intravenous administration of isoniazid in pulmonary tuberculosis].
    Zbants AN; Tsurkan VP; Mustiatsé NA; Kurochkin SIa; Ustiian AI
    Probl Tuberk; 1982 Dec; (12):45-8. PubMed ID: 7156122
    [No Abstract]   [Full Text] [Related]  

  • 39. [Possibilities of reducing the hospital-stage chemotherapy of patients with fibro-cavernous pulmonary tuberculosis].
    Naubet'iarova AN; Alibekova MKh
    Probl Tuberk; 1985; (3):38-40. PubMed ID: 4011589
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effectiveness of abbreviated biphasic treatment in pulmonary tuberculosis].
    Cramer G
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1981; 30(3):177-80. PubMed ID: 6273990
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.